COMP <GO>
NATR vs ABBV // FORWARD P/E MULTIPLE
Nature's Sunshine Products Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: NATR 5
— ABBV 8
▲ FORWARD P/E MULTIPLE LEADER: NATR
LAST: $12.25 (-0.24%) • MKT CAP: $216.1M
forward-pe
10.3x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NATR VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NATR | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 72.40% | 70.20% | +2.20 | NATR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 28.90% | 29.00% | -0.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 4.0x | 33.3x | -29.30 | NATR | /valuation <GO> |
| Free Cash Flow Yield | 13.35% | 3.47% | +9.88 | NATR | /fcf-yield <GO> |
| Operating Margin | 5.20% | 24.60% | -19.40 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 4.10% | 6.90% | -2.80 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 8.60% | -2.90 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.33 | 5.33 | -1.00 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | NATR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.8 | 65.1 | -23.34 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 10.3x | 113.1x | -102.80 | NATR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $216.1M | $513.86B | -$513.64B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NATR REV | ABBV REV | NATR GROSS % | ABBV GROSS % | NATR FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $480.1M | $61.16B | 72.4% | 70.2% | $28.8M | $17.82B |
| FY 2024 | $454.4M | $56.33B | 71.5% | 70.0% | $14.3M | $17.83B |
| FY 2023 | $445.3M | $54.32B | — | — | $41.2M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NATR // BETA —
ABBV // BETA 1.15